Abstract 1277P
Background
There is an unmet need for post-surgical therapeutic options in early-stage NSCLC patients. PARP inhibitors (PARPi) have shown efficacy in cancer patients harboring germline or/and somatic BRCA1/BRCA2 mutations and homologous recombination deficiency (HRD). Patient selection for targeted treatment is of crucial importance. Thus, the assessment of HRD status in patients with early-stage NSCLC may pave the way for the use of PARPi in an adjuvant setting.
Methods
Tumor specimens and peripheral blood samples were analyzed for somatic and germ-line mutations with a customized panel of 58 genes. To assess HRD status the genomic scar score (GSS) was calculated using the AmoyDx® HRD Focus Panel or AmoyDx® HRD Complete Panel. The effect of PARP inhibition on tumour growth was assessed in patient-derived xenografts, where RAD51 foci were quantified by immunofluorescence.
Results
Six of 85 patients (59 men/26 women) with operable NSCLC, carried germline mutations in BRCA1 (n=1), BRCA2 (n=1), ATM (n=3), and PALB2 (n=1) genes. Pathogenic somatic mutations were detected in BRCA1 (n=8), BRCA2 (n=9), ATM (n=8), PALB2 (n=3), CHEK1 (n=3), CHEK2 (n=6), RAD50 (n=5) and TP53 (n=49) genes. Based on GSS, 25 (29.4%) patients were characterized as HRD and at least one somatic HRR mutated gene was observed in 15 (57.7%) of them [BRCA1 (n=4), BRCA2 (n=4), ATM (n=3), PALB2 (n=2), CHEK2 (n=1) ]. Preliminary functional experiments in HRP (HR proficient, n=5) and HRD (n=4) PDX and organoids (n=3 and n=3 for HRD and HRP respectively) indicate that HRD tumors present low RAD51 foci count (p=0.03 after damage induction) and favorable response to Olaparib and CDDP.
Conclusions
These data suggest that homologous recombination may be deficient in a substantial proportion of early-stage NSCLC patients, supporting the potential use of PARPi in HRD patients in the adjuvant or maintenance setting.
Clinical trial identification
N/A
Editorial acknowledgement
N/A
Legal entity responsible for the study
The authors.
Funding
Amoy Diagnostics.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
488P - Comprehensive genomic profiling to identify actionable alterations for breast cancer brain metastases in the Chinese population
Presenter: Qianyi Lu
Session: Poster session 04
489P - Liquid biopsy with combination of cell & cell-free analysis identifies HER2-expression in patients with metastatic breast cancer
Presenter: Fengting Yan
Session: Poster session 04
491P - Comparison of ctDNA profiles from HR+/HER2-low and HR+/HER2-0 advanced breast cancer patients
Presenter: Nina Dobrić
Session: Poster session 04
492P - Wound stress stimulation promotes lung metastasis of breast cancer by regulating CXCL12/CXCR4 axis through MDSC exosome miR-126a-5p
Presenter: Xiaomeng Yin
Session: Poster session 04
493P - Identifying genomic changes in breast tumours that metastasise to the brain
Presenter: Ivonne Olivares
Session: Poster session 04
494P - Proviral insertion in murine 1 (PIM1) kinase expression and clinical outcomes in advanced breast cancer (ABC)
Presenter: Stephanie Graff
Session: Poster session 04
495P - Prognostic value of PIK3CA mutational status in tissue & plasma in HR+/HER2- breast cancer (BC)
Presenter: Rebeca Lozano Mejorada
Session: Poster session 04
496P - Comprehensive genomic profiling of advanced HR+/HER2- breast cancer patients using liquid biopsy
Presenter: Bin Shao
Session: Poster session 04
497P - Metastatic potential of the somatic alteration associated with TCA-cycle in breast cancer
Presenter: Narumi Harada
Session: Poster session 04